Noubar Afeyan, Director, 10% Owner at Generate Biomedicines, Inc. (GENB), bought 1,562,500 shares at $16.00 ($25.0M) on 2026-03-02, disclosed to the SEC on 2026-03-02.
Noubar Afeyan purchased $25 million of GENB at $16.00, marking the largest insider purchase in the company's history. This significant bet suggests management sees value in the generative biology platform despite recent stock weakness.
The stock is currently trading 20.56% below its 52-week high of $15.32 and 6.38% above its 52-week low of $11.44.
The company reported a net loss of $249.5 million in its latest report, and the stock carries a short interest of 4.63% of the float.
Something here stands out, but not much.
| Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |
| MRNA | SELL | 2024-07-19 | $3.0M | — | Filing → |